EXPRESSION OF TUMOR-ASSOCIATED 90K-ANTIGEN IN HUMAN BREAST-CANCER - NO CORRELATION WITH PROGNOSIS AND RESPONSE TO FIRST-LINE THERAPY WITH TAMOXIFEN

Citation
Ja. Foekens et al., EXPRESSION OF TUMOR-ASSOCIATED 90K-ANTIGEN IN HUMAN BREAST-CANCER - NO CORRELATION WITH PROGNOSIS AND RESPONSE TO FIRST-LINE THERAPY WITH TAMOXIFEN, International journal of cancer, 64(2), 1995, pp. 130-134
Citations number
25
Categorie Soggetti
Oncology
ISSN journal
00207136
Volume
64
Issue
2
Year of publication
1995
Pages
130 - 134
Database
ISI
SICI code
0020-7136(1995)64:2<130:EOT9IH>2.0.ZU;2-P
Abstract
It has been shown that a 90-kDa protein (90K), with an as yet unknown function, is expressed in the majority of human breast-cancer tissues. In addition, the serum level of this 90K antigen is elevated in a cer tain proportion of breast-cancer patients, and high serum levels are a ssociated with a poor overall survival. It was therefore of interest t o determine whether levels of 90K in tumor tissues could be used as a prognostic variable in breast cancer. In the present study, the levels of 90K in primary breast tumor cytosols were studied with respect to the length of relapse-free or overall survival in 547 patients (median follow-up, 81.4 months), and the relationship with response to first- line tamoxifen therapy and the length of progression-free survival in 184 patients with recurrent disease (median follow-up, 59.8 months). 9 0K levels in tumor cytosols were determined with an immunoradiometric assay. The cytosolic contents of 90K were not significantly correlated with age, menopausal status, tumor size, nodal status or differentiat ion grade. On the other hand, the levels of 90K were positively correl ated with those of cytosolic estrogen receptor, progesterone receptor, urokinase-type plasminogen activator, its inhibitor PAI-1, cathepsin D and PSZ. The cytosolic tumor level of 90K was not associated with th e rate of relapse or death in primary breast cancer, nor with response to first-line therapy with tamoxifen or the length of progression-fre e survival in recurrent disease. (C) 1995 Wiley-Liss, Inc.